Search Results for: Carcinoma mammario in fase iniziale

Nei pazienti con anemia emolitica autoimmune da anticorpi caldi (wAHIA), il trattamento con l’inibitore della tirosin chinasi di Bruton (BTK) rilzabrutinib è efficace, anche nel lungo termine, nel migliorare i valori di emoglobina (Hb), ridurre i biomarcatori di emolisi e migliorare la fatigue, con un buon profilo di sicurezza. Lo dimostrano i risultati di una nuova analisi dello studio di fase 2b LUMINA 2, con un periodo più lungo di osservazione, presentati di recente a Milano, in occasione del congresso annuale della European Hematology Association (EHA).

In Italia, il carcinoma della prostata rappresenta la neoplasia più diffusa tra gli uomini over 50, incidendo per circa il 30% su tutti i tumori maschili, con 40.192 nuovi casi stimati solo nel 2024. È stata presentata oggi, in Senato la campagna di sensibilizzazione ‘Allo Specchio della Salute – uno spazio di confronto sul carcinoma prostatico’, pensata per coinvolgere l’intera comunità nel dibattito intorno alla gestione e cura di questa patologia. Un’intera giornata dedicata al carcinoma della prostata suddivisa in due appuntamenti sinergici e xomplementari: la conferenza stampa seguita dalla campagna di awareness.

Nelle pazienti con carcinoma mammario metastatico, una nuova terapia ormonale mirata, elacestrant, ha ridotto il rischio di progressione o morte del 45%. L’Agenzia Italiana del Farmaco (AIFA) ha approvato la rimborsabilità di elacestrant per il trattamento di donne in postmenopausa, e di uomini, con carcinoma mammario localmente avanzato o metastatico positivo per i recettori degli estrogeni (ER+) e negativo per la proteina HER2 (HER2-), con una mutazione attivante del gene ESR1, che mostrano progressione della malattia in seguito ad almeno una linea di terapia endocrina comprendente un inibitore delle cicline CDK 4/6.

Il carcinoma gastrico rappresenta una neoplasia aggressiva con una prognosi particolarmente infausta sia per la frequente presentazione in fase avanzata, sia per l’elevato tasso di recidive, anche dopo chirurgia radicale:…

Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and mortality rates have continued to rise despite advancements in treatment. Six-monthly ultrasound surveillance is recommended by professional bodies for early detection of HCC in high-risk cohorts. However, surveillance rates remain poor; only 20% of patients attend for regular surveillance. Population health outreach strategies may be able to enhance surveillance rates by addressing patient-related barriers to engagement with healthcare. Using a co-design approach, we have developed outreach material in tandem with patients, with the aim of boosting HCC surveillance. VIGILANT aims to compare the effectiveness of bespoke mailed surveillance invitations with or without patient navigators (PNs) in improving attendance rates at surveillance appointments.

Methods and analysis
This is a two-arm randomised controlled trial that will recruit 652 participants. Participants will be patients with chronic liver disease or cirrhosis, who are eligible for HCC surveillance as defined by criteria from the National Institute for Health and Care Excellence and European Association for the Study of the Liver. Participants will be randomised (in a 1:1 ratio) to receive either (a) a mailed surveillance invitation or (b) a mailed invitation plus telephone call reminder from a PN 1 week prior to the appointment. The primary objective is to evaluate the impact of PNs and mailed invitations on attendance rates. Secondary objectives include rates of diagnosis of early-stage HCC among patients undergoing surveillance and cost-effectiveness of each arm.

Ethics and dissemination
Approval has been sought to conduct the research from Aberdeen Research Ethics Committee (REC Reference: 335338). The study is sponsored by Imperial College London and funded by RM Partners (West London Cancer Alliance). Study findings will be presented at medical conferences and published in peer-reviewed journals.

Trial registration number
NCT06635694.

Per la fase avanzata. Al San Carlo di Potenza

Risultati incoraggianti da studio fase 3 su sotatercept

Atrofia muscolare spinale, risultati positivi da studio fase 1

Introduction
Surgical resection is the cornerstone therapy for pancreatic neoplasms, particularly in cases of resectable pancreatic carcinoma identified in the early stages. Clinically relevant postoperative pancreatic fistula (CR-POPF) persists as a prevalent and formidable postsurgical complication, substantially elevating patient morbidity and mortality. The current literature reveals a gap in the understanding of the relationship between perioperative glucose levels and the incidence of CR-POPF in patients undergoing pancreatic surgery. This study aims to investigate the association between perioperative glycaemic levels, specifically monitoring both blood and interstitial fluid glucose levels via non-invasive continuous glucose monitoring (CGM) and the occurrence of CR-POPF.

Methods and analysis
This observational prospective cohort study will be conducted at high-volume general hospitals in China. Adult patients scheduled for elective pancreatic surgeries from 1 March 2024 to 31 March 2025 will be prospectively enrolled, and the end date of the whole study is 31 July 2025. Eligible patients will wear a CGM system before surgery, and real-time interstitial fluid blood glucose levels will be monitored up to 14 days after surgery, or until the patient is discharged from the hospital. Patient characteristics and perioperative data will be collected using a standard case report form. The primary outcome is the incidence of CR-POPF during the hospital stay. The secondary outcomes include other postoperative complications, such as bile leakage, chyle leak, postoperative haemorrhage, intra-abdominal infection, and delayed gastric emptying, and in-hospital mortality.

Ethics and dissemination
The study protocol was approved by the Research Ethics Committee of Peking Union Medical College Hospital (IRB K-2501). Written informed consent will be obtained from all participants before study enrolment. The results of this study will be disseminated at scientific conferences and published in international peer-reviewed journals.

Trial registration number
NCT06289530.

Nuovo questionario GastroForm per identificare persone a rischio

Nuovo questionario GastroForm per identificare persone a rischio

To the Editor The COMET trial compared active monitoring with guideline-concordant care in patients with low-risk ductal carcinoma in situ (DCIS).

In Reply The Letter from Dr Lin and colleagues raises important points regarding the recent publication of the COMET trial for low-risk DCIS that merit further consideration.

Hepatocellular carcinoma (HCC) is often diagnosed at the unresectable stage with limited treatment options.1 Immunotherapy with immune checkpoint blockade (ICB) has been shown to provide significant survival benefit for HCC patients with advanced disease. Two combination therapies of anti-PD-L1 plus anti-VEGF or anti-PD1 plus anti-CTLA4 represent the current first-line treatments for unresectable HCC.2 3 However, only about one-third of patients respond to therapy, typically in the context of immune-enriched (‘hot’) tumour microenvironments.4 5 Therefore, there is a major need for treatment strategies that overcome ICB resistance. In Gut, Tu et al observe a correlation of poor prognostic outcomes by anti-PD-1-treated patients with high expression of major histone deacetylases (HDACs) by HCC tumours.6 They, therefore, test the potential of epigenetic immunotherapy combining HDAC inhibitors with ICB therapy in preclinical animal models and provide evidence that the epigenetic immunotherapy…